Mode
Text Size
Log in / Sign up
Phase 3 N=220 Randomized Double-blind Treatment

Comparison of Processed Nerve Allograft and Collagen Nerve Cuffs for Peripheral Nerve Repair

Peripheral Nerve Discontinuities

Enrolled (actual)
220
Serious AEs
3.6%
Results posted
Jul 2023
Primary outcome: Primary: Static Two-Point Discrimination (Pre-defined Mixed Modeling Approach) — 9.1; 9.3 Millimeters

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
Processed Nerve Allograft (human) (Biological); Collagen Nerve Cuff (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Axogen Corporation
Primary completion
Aug 2021

Outcome Measures

OutcomeResultp-value
PRIMARY
Static Two-Point Discrimination (Pre-defined Mixed Modeling Approach)
9.1; 9.3
PRIMARY
Static Two-Point Discrimination (Data As-reported)
7.3; 7.5; 6.1; 7.5 0.035 sig
SECONDARY
Response Rate for Recovery of s2PD at Month 12 (Data As-Reported)
77.5; 77.2 0.915
SECONDARY
Percent Recovery to Pre-Injury Baseline (Contralateral Control Value) s2PD at Month 12 (Pre-defined Modeling Approach)
54.46; 51.67
SECONDARY
Time to Recovery of s2PD (Data As-reported)
8.0; 7.8 0.792
SECONDARY
Medical Research Council (MRC) Classification for Sensory Function Scores at Month 12 (Data As-reported)
4.0; 4.0 0.526
SECONDARY
Change in Pain Visual Analogue Scale (VAS) Scores at Month 12 (Pre-defined Modeling Approach)
-24.09; -24.94

Summary

Processed Nerve Allograft and Collagen Nerve Cuffs will be compared to assess safety and functional outcomes for the repair of nerve injuries in the hand.

Eligibility Criteria

Inclusion Criteria

  • Peripheral Nerve Injury

Exclusion Criteria

  • Peripheral Neuropathy
  • Allergic to Bovine products such as Bovine Collagen Nerve Cuff
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01809002). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search